AstraZeneca's anti-Covid reveals gives positive effect over disease risk in vulnerable patients
AstraZeneca acquired sipavibart from RQ Bio in May 2022
AstraZeneca acquired sipavibart from RQ Bio in May 2022
The vaccine, developed by AstraZeneca and Oxford University, was produced by the Serum Institute of India as Covishield
Despite these rare occurrences, the pharmaceutical company maintains that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy
The pharmaceutical giant has sold the vaccine globally under the brand names Covishield and Vaxzevria among others
<p>Mexico received a shipment of 870,000 doses of AstraZeneca’s COVID-19 vaccine from India yesterday. The government said that the country prepares to prioritize older people in the next phase of its vaccination campaign. Foreign Minister Marcelo Ebrard told a news conference that the country is also expecting shipments to resume of vaccine from Pfizer-BioNTech , […]</p>